Named Patient Program for Mitomycin for Pyelocalyceal Solution
This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.
Urothelial Cancer of Renal Pelvis|Urothelial Carcinoma of the Renal Pelvis and Ureter|Urothelial Carcinoma Ureter|Urothelial Carcinoma Ureter Recurrent|Urothelial Carcinoma|Urothelial Carcinoma Recurrent
DRUG: Mitomycin for pyelocalyceal solution
This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.